株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非侵襲癌診断市場:2015〜2030年

Non-Invasive Cancer Diagnostics Market, 2015 - 2030

発行 ROOTS ANALYSIS 商品コード 344666
出版日 ページ情報 英文 229 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
非侵襲癌診断市場:2015〜2030年 Non-Invasive Cancer Diagnostics Market, 2015 - 2030
出版日: 2015年10月20日 ページ情報: 英文 229 Pages
概要

非侵襲癌診断市場は、主にリキッドバイオプシーに促進され、2015年から2030年にかけて44%の年間成長率で好調な成長を示すと予測されています。前立腺癌、乳癌、結腸直腸癌、および肺癌は、これらの合計が2030年におけるリキッドバイオプシー市場全体の70%以上を構成すると予測されることから、同市場を促進する主な指標となる見込みです。

当レポートは、世界の非侵襲癌診断市場について取り上げ、各種の癌診断に用いられる上市・開発中のリキッドバイオプシーキット/アッセイ、およびその他の新しい・有望な非侵襲診断に関する調査を提供しており、市場の概要、市場規模と予測、および主要企業のプロファイルなどをまとめ、お届け致します。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 癌統計・疾病負担
  • 癌における早期発見の重要性
  • 癌検出:検査 vs. 診断
  • 従来型の侵襲性癌診断検査
    • 生検
    • 内視鏡
  • 非侵襲アプローチの必要性

第4章 非侵襲癌スクリーニング・診断のコンセプト

  • 本章の概要
  • 診断画像
  • スクリーニングアッセイ
  • 先進非侵襲アプローチ

第5章 市場概要

  • 本章の概要
  • リキッドバイオプシー
  • リキッドバイオプシー技術・システム/装置
  • その他の非侵襲癌診断検査:市場環境

第6章 リキッドバイオプシー:詳細展望

  • 本章の概要
  • 生検を超える癌の非侵襲検出
  • 癌の血中循環バイオマーカー
  • リキッドバイオプシーに基づいた技術、システムおよび検査

第7章 その他の新しい非侵襲技術

  • 本章の概要
  • 画像ベースの診断
  • バイオマーカー・ヌクレオソーム検出
  • 皮膚病変ベースの診断
  • 診断用呼気検査

第8章 市場規模・予測

  • 本章の概要
  • 調査手法
  • 全体的な非侵襲癌診断市場
  • リキッドバイオプシー市場
  • 重要適応症の機会分析
  • 非侵襲癌診断市場:地域配分

第9章 企業プロファイル

  • 本章の概要
  • リキッドバイオプシーにフォーカスした企業
  • その他の非侵襲癌診断技術にフォーカスした企業

第10章 結論

第11章 インタビュー記録

第12章 付録1:表形式のデータ

第13章 付録2:企業と組織の一覧

図表

目次
Product Code: RA10048

Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors influencing the disease origin, propagation, spread (metastasis) and relapse. In addition to satisfying the unmet market need for advanced and efficient treatment interventions, cancer prevention, early detection and management is extremely important. The high cancer mortality rate is primarily due to delay in detection of the disease.Early diagnosis and screening makes it possible to cure the disease completely and/or increase survival rates.Over the years, various technological advances have helped medical professionals understand cancer better. Recent research in cancer biology has led to a lot of innovation in the development of a number of new diagnostic tools. These modern diagnostic techniques can help detect and classify cancer with increased accuracy and sensitivity.

It is also important to highlight that the cost of management and treatment of cancer is a growing concern considering its highly progressive and fatal nature.Performing a biopsy includes costs associated with the equipment, cost of the procedure itself, consultation fees, hospital fees, costs of analyticaltests and those associated with post-operative care.To manage this financial burden, the introduction of novel non-invasive techniques, which are cost-effective and more accurate, has become an indispensable necessity.

There are several advanced approaches, which are non-invasive or minimally invasivein nature, and these outweigh the limitations posed by invasive diagnostic procedures.Specifically, liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool for early detection as well as monitoring the disease's progress. This technique of tracing the presence of circulating biomarkers in blood and other biological fluids of cancer patients is becoming increasingly popular in the medical fraternity.In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies. These include techniques based on molecular imaging, advanced genomic and transcriptomic methods of detection of clinically significant biomarkers and identification of nucleosomal levels. All such non-invasive tests hold a significant promise to enhance the quality of patient care.

Synopsis

The 'Non-Invasive Cancer Diagnostics Market, 2015-2030' report provides an extensive study on liquid biopsy kits/assays that are either commercialised or under development for the diagnosis of different types of cancer. Liquid biopsy primarily focuses on the detection, isolation and characterisation of biomarkers from circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) or exosomes present in biological fluids, which can be collected in a single blood draw. The market is characterised by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or molecular characterisation/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, patient and recurrence monitoring. It is important to stress that even though liquid biopsy has still not made a strong foothold in the field of oncology, it is likely to transform the cancer diagnostics market with many commercial success stories in the near future.

In addition to liquid biopsy, there are several other novel and promising non-invasive diagnostics being developed for the diagnosis and prognosis of cancer. However, these tests are only indicative of the disease and may require further validation through more robust diagnostic methods such as biopsy. These tests retrieve the test sample non-invasively and use innovative techniques to screen for the desired parameters indicative of the disease with a moderate level of accuracy. Some of these are designed to be used at home by the patient itself.

As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analysing:

  • The global burden of cancer in terms of incidence and prevalence of different cancer indications across different geographies.
  • The overall landscape of liquid biopsies and other novel diagnostic tests with respect to the type of analysis (CTCs/ctNA/exosomes), test sample source (blood/urine/others) and indications.
  • The likely global evolution of the liquid biopsy market taking into account initial diagnosis, recurrence monitoring and patient monitoring.
  • Contribution of other novel diagnostic tests in the non-invasive cancer diagnostics market and the market opportunity of the key indications influencing the overall growth.

We have provided three market forecast scenarios for the time period 2015-2030. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. Our opinions and insights, presented in this study, were influenced by discussions that we conducted with experts in this area. All actual figures have been sourced and analysed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. We have identified over 50 liquid biopsy tests; some of these are commercialised and the rest are currently under development. Of these, 50% tests are based on the identification of disease biomarkers in ctDNA of the test sample. Nearly 37% of the tests are based on the enumeration/analysis of CTCs in the sample and the remaining 13% validate the presence of the disease from the information obtained from exosomes.
  • 2. Several companies are developing systems and instruments to support the detection, isolation and characterisation of rare cells. Examples include (in no specific order) the Parsortix System by ANGLE, ScreenCell® Isolation Devices by ScreenCell, ApoStream™ System by ApoCell, ClearCell FX® System by ClearbridgeBioMedics and iCellate® Instrument by iCellate Medical.
  • 3. Firms have also taken initiatives and entered into collaborations to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between Tokai Pharmaceuticals and Qiagen, AstraZeneca and Qiagen, SysmexInostics and Bayer HealthCare.
  • 4. In addition to liquid biopsy, we have identified close to 40 other non-invasive cancer diagnostics that are used for screening, diagnosis, prognosis and patient monitoring; these include techniques based on molecular imaging, advanced methods of detecting clinically significant biomarkers and identification of nucleosomal levels.
  • 5. Primarily driven by liquid biopsy, the non-invasive cancer diagnostics market is anticipated to grow aggressively ata healthy annual growth rate of 44% between 2015 and 2030. Prostate cancer, breast cancer, colorectal cancer and lung cancer are likely to be the key indications which will drive the market; combined, these are expected to account for over 70% of the total liquid biopsy market in 2030.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

Chapter 3 provides a general introduction to cancer statistics and burden of the disease worldwide. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses in detail the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

Chapter 5 provides a holistic view of the non-invasive cancer diagnostics landscape. It enlists the liquid biopsy tests, technologies and systems. In addition, it offers a list of other non-invasive tests. These lists include information on the developer, technology used by the product, test sample source and indication. We have also mapped the geographical presence of the enlisted non-invasive cancer diagnostics developers.

Chapter 6 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages and challenges. In addition, we have provided technology profiles and product profiles of several liquid biopsy products. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

Chapter 7 provides an overview of the other novel non-invasive diagnostics used in oncology. It highlights the different imaging based diagnostic procedures, biomarker and nucleosome based diagnostics, skin lesion and breath based diagnostics. The diagnostic procedures discussed in this chapter are backed up by several examples.

Chapter 8 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters likely to influence the evolution of liquid biopsy market. In addition, we have also presented the market share of other non-invasive diagnostic tests and an opportunity analysis for the key indications likely to have the maximum impact on the overall market.

Chapter 9 provides detailed company profiles of the leading players in the market involved in the development of liquid biopsy as well as other non-invasive tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio and recent collaborations.

Chapter 10 summarises the overall report. In this chapter, we list the key takeaways and provide our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is a collection of interview transcripts of the discussions that were held during the course of this study.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides the list of companies and organisations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Cancer Statistics and Burden of the Disease
  • 3.3. Importance of Early Detection in Cancer
  • 3.4. Detecting Cancer: Screening versus Diagnosis
  • 3.5. Conventional Invasive Cancer Diagnostic Tests
    • 3.5.1. Biopsy
    • 3.5.2. Endoscopy
  • 3.6. Need for Non-Invasive Approaches

4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS

  • 4.1. Chapter Overview
  • 4.2. Diagnostic Imaging
    • 4.2.1. Magnetic Resonance Imaging (MRI)
    • 4.2.2. Mammography
    • 4.2.3. Bone Scan
    • 4.2.4. Computerised Tomography (CT) Scan
    • 4.2.5. Integrated PET-CT Scan
    • 4.2.6. Ultrasound
    • 4.2.7. Barium Enema
  • 4.3. Screening Assays
    • 4.3.1. Pap Test and HPV Test
    • 4.3.2. Tumour Marker Tests
    • 4.3.3. Faecal Occult Blood Tests (FOBT)
    • 4.3.4. Digital Rectal Exam (DRE)
    • 4.3.5. MUGA Scan
  • 4.4. Advanced Non-Invasive Approaches
    • 4.4.1. Liquid Biopsy
    • 4.4.2. Cytogenetic/Gene Expression Studies
    • 4.4.3. Molecular Signature Based Non-Invasive Methods
    • 4.4.4. Saliva-Based Oral Cancer Diagnostics
    • 4.4.5. Vital Staining
    • 4.4.6. Optical Biopsy
    • 4.4.7. Other Techniques

5. MARKET OVERVIEW

  • 5.1. Chapter Overview
  • 5.2. Liquid Biopsy: Market Landscape
    • 5.2.1. Liquid Biopsy: Distribution by Type of Analysis
    • 5.2.2. Liquid Biopsy: Distribution by Sample Source
    • 5.2.3. Liquid Biopsy: Distribution by Indication
    • 5.2.4. Liquid Biopsy: Distribution by Region
  • 5.3. Liquid Biopsy Technologies and Systems/Instruments
  • 5.4. Other Non-Invasive Cancer Diagnostic Tests: Market Landscape
    • 5.4.1. Other Non-Invasive Tests: Distribution by Sample Source
    • 5.4.2. Other Non-Invasive Tests: Distribution by Indication
    • 5.4.3. Other Non-Invasive Tests: Distribution by Region

6. LIQUID BIOPSY: DETAILED OUTLOOK

  • 6.1. Chapter Overview
  • 6.2. Non-Invasive Detection of Cancer over Biopsies
  • 6.3. Circulating Biomarkers for Cancer
    • 6.3.1. CTCs and ctcDNA
    • 6.3.2. ctDNA
    • 6.3.3. Exosomes
  • 6.4. Liquid Biopsy Based Technology, Systems and Tests
    • 6.4.1. ApoStream® Technology and ApoStream® CTC Test (ApoCell)
      • 6.4.1.1. Overview
      • 6.4.1.2. Results
      • 6.4.1.3. Collaborations
      • 6.4.1.4. Funding
    • 6.4.2. BioFluidica CTC Isolation Technology and CTC Analysis System (BioFluidica/Roche)
      • 6.4.2.1. Overview
      • 6.4.3.2. Results
      • 6.4.3.3. Collaborations
    • 6.4.3. CELLSEARCH® System and CELLSEARCH® CTC Test (Janssen Diagnostics)
      • 6.4.3.1. Overview
      • 6.4.3.2. Results
      • 6.4.3.3. Collaborations
      • 6.4.3.4. Other Developments
    • 6.4.4. LiquidBiopsy® Rare Cell Isolation Platform and ClearID Test (CynvenioBiosystems)
      • 6.4.4.1. Overview
      • 6.4.4.2. Collaborations
      • 6.4.4.3. Other Developments
      • 6.4.4.4. Funding
    • 6.4.5. Parsortix System (ANGLE)
      • 6.4.5.1. Overview
      • 6.4.5.2. Results
      • 6.4.5.3. Collaborations
      • 6.4.5.4. Funding
    • 6.4.6. QuantiGene® ViewRNA CTC Platform and Assay (Affymetrix)
      • 6.4.6.1. Overview
      • 6.4.6.2. Collaborations
    • 6.4.7. IVDxTx Platform Technology and IVD CTC Assays (IVDiagnostics)
      • 6.4.7.1. Overview
      • 6.4.7.2. Collaborations
      • 6.4.7.3. Other Developments
      • 6.4.7.4. Funding
    • 6.4.8. iCellate® (iCellate AB)
      • 6.4.8.1. Overview
      • 6.4.8.2. Collaborations
    • 6.5. Liquid Biopsy and Companion Diagnostic Products
      • 6.5.1. Tokai Pharmaceuticals and Qiagen
      • 6.5.2. AstraZeneca and Qiagen
      • 6.5.3. SysmexInostics and Bayer HealthCare

7. OTHER NOVEL NON-INVASIVE TECHNOLOGIES

  • 7.1. Chapter Overview
  • 7.2. Imaging Based Diagnostics
  • 7.3. Biomarker and Nucleosome Detection
  • 7.4. Skin Lesion Based Diagnosis
  • 7.5. Diagnostic Breath Testing

8. MARKET SIZING AND FORECAST

  • 8.1. Chapter Overview
  • 8.2. Methodology
  • 8.3. Overall Non-Invasive Cancer Diagnostic Market
  • 8.4. Liquid Biopsy Market
    • 8.4.1. Initial Diagnosis
    • 8.4.2. Recurrence Monitoring
    • 8.4.3. Patient Monitoring
    • 8.4.4. Market Forecast Projections, 2015-2030
  • 8.5. Opportunity Analysis for Important Indications
    • 8.5.1. Prostate Cancer
    • 8.5.2. Breast Cancer
    • 8.5.3. Colorectal Cancer
    • 8.5.4. Lung Cancer
  • 8.6. Non-Invasive Cancer Diagnostics Market: Regional Distribution

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Companies with Focus on Liquid Biopsy
    • 9.2.1. Biocept
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Performance
      • 9.2.1.3. Product Portfolio
      • 9.2.1.4. Collaborations
    • 9.2.2. Exosome Diagnostics
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Product Portfolio
      • 9.2.2.3. Collaborations
    • 9.2.4. Genomic Health
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Financial Performance
      • 9.2.4.3. Product Portfolio
      • 9.2.4.4. Collaborations
    • 9.2.5. Guardant Health
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Product Portfolio
      • 9.2.5.3. Collaborations
    • 9.2.6. Qiagen
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Performance
      • 9.2.6.3. Product Portfolio
      • 9.2.6.4. Collaborations
    • 9.2.7. Trovagene
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Performance
      • 9.2.7.3. Product Portfolio
      • 9.2.7.4. Collaborations
  • 9.3. Companies with Focus on Other Non-Invasive Diagnostic Techniques
    • 9.3.1. bioMérieux
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Portfolio
      • 9.3.1.4. Collaborations
    • 9.3.2. Cepheid
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Portfolio
      • 9.3.2.4. Collaborations
    • 9.3.3. DermTech
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Product Portfolio
      • 9.3.3.3. Collaborations
    • 9.3.4. DiagnoCure
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Portfolio
      • 9.3.4.4. Collaborations
    • 9.3.5. Exact Sciences
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Portfolio
      • 9.3.5.4. Collaborations
    • 9.3.7. Pacific Edge
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Portfolio
      • 9.3.7.4. Collaborations

10. CONCLUSION

  • 10.1. Improved Cancer Detection and Patient Care: A Growing Necessity
  • 10.2. Introduction of Sophisticated Molecular Diagnostics: A Solution to the Existing Unmet Need
  • 10.3. Liquid Biopsy: The Potential Replacement to Invasive Techniques
  • 10.4. Other Non-Invasive Tests: Further Enhancing the Cancer Diagnostics Portfolio
  • 10.5 With Liquid Biopsy at the Forefront, Non-Invasive Cancer Diagnostics Expected to Emerge as a Multi-Billion Dollar Market

11. INTERVIEW TRANSCRIPTS

  • 11.1. Christer Ericsson, Chief Scientific Officer, iCellate AB
  • 11.2. Philippe Nore, CEO and Co-founder, MiNDERA Corporation
  • 11.3. Dr. Jake Micallef, Chief Scientific Officer, VolitionRx

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

  • Figure 3.1 Worldwide Incidence: Distribution by Type of Cancer
  • Figure 3.2 Lung Cancer: Estimated New Cases in 2015 (in'000s)
  • Figure 3.3 Breast Cancer: Estimated New Cases in 2015 (in '000s)
  • Figure 3.4 Colorectal Cancer: Estimated New Cases in 2015 (in '000s)
  • Figure 3.5 Factors Determining Useful Cancer Screening
  • Figure 3.6 Conventional Cancer Diagnosis Methods
  • Figure 3.7 Needle Biopsy and Open Biopsy: Demerits
  • Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
  • Figure 4.2 Types of Diagnostic Imaging
  • Figure 4.3 Types of Screening Assays
  • Figure 4.4 Types of Advanced Non-Invasive Approaches
  • Figure 5.1 Liquid Biopsy: Distribution by Type of Analysis
  • Figure 5.2 Liquid Biopsy: Distribution by Sample Source
  • Figure 5.3 Liquid Biopsy: Distribution by Indication
  • Figure 5.4 Liquid Biopsy: Distribution by Region
  • Figure 5.5 Other Non-Invasive Tests: Distribution by Sample Source
  • Figure 5.6 Other Non-Invasive Tests: Distribution by Indication
  • Figure 5.7 Other Non-Invasive Tests: Distribution by Region
  • Figure 6.1 Circulating Biomarkers for Cancer
  • Figure 6.2 ApoStream® Technology: Advantages
  • Figure 6.3 BioFluidica CTC Isolation System Workflow
  • Figure 6.4 BioFluidica System: Advantages
  • Figure 6.5 CELLSEARCH® System: Basic Steps
  • Figure 6.6 CELLSEARCH® System Workflow
  • Figure 6.7 LiquidBiopsy® Workflow
  • Figure 6.8 LiquidBiopsy® and Ion Torrent PGM Workflow Components
  • Figure 6.9 Parsortix System Workflow
  • Figure 6.10 ViewRNA CTC Platform Workflow
  • Figure 6.11 iCellate® Workflow
  • Figure 8.1 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
  • Figure 8.2 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
  • Figure 8.3 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
  • Figure 8.4 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
  • Figure 8.5 Prostate Cancer Liquid Biopsy Market (USD Million)
  • Figure 8.6 Breast Cancer Liquid Biopsy Market (USD Million)
  • Figure 8.7 Colorectal Cancer Liquid Biopsy Market (USD Million)
  • Figure 8.8 Lung Cancer Liquid Biopsy Market (USD Million)
  • Figure 8.9 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
  • Figure 8.10 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
  • Figure 9.1 Biocept Revenues, 2012- H1 2015 (USD Million)
  • Figure 9.2 Genomic Health Revenues, 2010- H1 2015 (USD Million)
  • Figure 9.3 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
  • Figure 9.4 Qiagen Revenues, Q1 2015, Distribution by Business Segments (Share in %)
  • Figure 9.5 Trovagene Revenues, 2010-Q1 2015 (USD Million)
  • Figure 9.6 bioMérieux Revenues, 2011-Q1 2015 (EUR Billion)
  • Figure 9.7 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
  • Figure 9.8 Cepheid Revenues, 2010- H1 2015 (USD Million)
  • Figure 9.9 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
  • Figure 9.10 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
  • Figure 9.11 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
  • Figure 9.12 Pacific Edge Revenues, 2010-2014 (USD Million)
  • Figure 9.13 Cxbladder®: Biomarker Genes
  • Figure 10.1 Non-Invasive Cancer Diagnostic Market (USD Million), 2015, 2022 and 2030

List of Tables

  • Table 3.1 Survival on Early Diagnosis of Cancer
  • Table 3.2 Cost of Biopsy for Different Cancer Indications
  • Table 3.3 Common Endoscopic Procedures
  • Table 4.1 Examples of Tumour Markers
  • Table 5.1 Non-Invasive Cancer Diagnostics: Liquid Biopsy Tests
  • Table 5.2 Non-Invasive Cancer Diagnostics: Liquid Biopsy Technologies
  • Table 5.3 Non-Invasive Cancer Diagnostics: Liquid Biopsy Systems/ Instruments
  • Table 5.4 Non-Invasive Cancer Diagnostics: Other Screening and Diagnostic Tests
  • Table 6.1 Aspects of Biopsies versus Liquid Biopsies
  • Table 6.2 Liquid Biopsy Based Diagnostics: Example List
  • Table 6.3 Comparison between ApoStream CTC Test and CELLSEARCH® CTC Test
  • Table 6.4 ApoCell: Funding Instances
  • Table 6.5 Comparison of the Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
  • Table 6.6 CELLSEARCH® CTC Test: Cut-offs For Disease Prognosis
  • Table 6.7 CynvenioBiosystems: Funding Rounds
  • Table 6.8 ANGLE: Funding Rounds
  • Table 6.9 IVD CTC Tests: Potential Indications
  • Table 6.10 IVDiagnostics: Funding Rounds
  • Table 7.1 Sensitivity/Specificity: Individual Technologies versus Combination
  • Table 7.2 Imaging Based Diagnostics: Example List
  • Table 7.3 Biomarker and Nucleosome Detection Based Diagnostics: Example List
  • Table 7.4 Skin Lesion Based Diagnostics: Example List
  • Table 7.5 Diagnostic Breath Testing Devices: Example List
  • Table 8.1 Liquid Biopsy for Initial Diagnosis: Market Forecast Assumptions
  • Table 8.2 Liquid Biopsy for Recurrence Monitoring: Market Forecast Assumptions
  • Table 8.3 Liquid Biopsy for Patient Monitoring: Market Forecast Assumptions
  • Table 9.1 Q1Aamp® Circulating Nucleic Acid Kit: Specifications
  • Table 9.2 VIDAS® Tumour Markers: Specifications
  • Table 9.3 VIDAS® Tumour Markers, 2011-2014
  • Table 9.4 Xpert® HPV: Comparative Clinical Performance
  • Table 9.5 ImmunoCyt™/uCYT+™: Comparison with Other Urinary Cancer Biomarker Assays
  • Table 9.6 PCA3 Test: Launch Years for Respective Geographies
  • Table 12.1 Worldwide Incidence: Distribution by Type of Cancer
  • Table 12.2 Lung Cancer: Estimated New Cases in 2015 (in '000s)
  • Table 12.3 Breast Cancer: Estimated New Cases in 2015 (in '000s)
  • Table 12.4 Colorectal Cancer: Estimated New Cases in 2015 (in '000s)
  • Table 12.5 Liquid Biopsy: Distribution by Type of Analysis
  • Table 12.6 Liquid Biopsy: Distribution by Sample Source
  • Table 12.7 Liquid Biopsy: Distribution by Indication
  • Table 12.8 Liquid Biopsy: Distribution by Region
  • Table 12.9 Other Non-Invasive Diagnostic Tests: Distribution by Sample Source
  • Table 12.10 Other Non-Invasive Diagnostic Tests: Distribution by Indication
  • Table 12.11 Other Non-Invasive Diagnostic Tests: Distribution by Region
  • Table 12.12 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Base Case, 2015-2022
  • Table 12.13 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Base Case, 2022-2030
  • Table 12.14 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Optimistic Case, 2015-2022
  • Table 12.15 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
  • Table 12.16 Non-Invasive Cancer Diagnostic Market (USD Million), Short Term, Conservative Case, 2015-2022
  • Table 12.17 Non-Invasive Cancer Diagnostic Market (USD Million), Mid-Long Term Conservative Case, 2022-2030
  • Table 12.18 Liquid Biopsy Market (USD Million), Short Term, Base Case, 2015-2022
  • Table 12.19 Liquid Biopsy Market (USD Million), Mid-Long Term, Base Case, 2022-2030
  • Table 12.20 Liquid Biopsy Market (USD Million), Short Term, Optimistic Case, 2015-2022
  • Table 12.21 Liquid Biopsy Market (USD Million), Mid-Long Term, Optimistic Case, 2022-2030
  • Table 12.22 Liquid Biopsy Market (USD Million), Short Term, Conservative Case, 2015-2022
  • Table 12.23 Liquid Biopsy Market (USD Million), Mid Long Term, Conservative Case, 2022-2030
  • Table 12.24 Prostate Cancer Liquid Biopsy Market (USD Million)
  • Table 12.25 Breast Cancer Liquid Biopsy Market (USD Million)
  • Table 12.26 Colorectal Cancer Liquid Biopsy Market (USD Million)
  • Table 12.27 Lung Cancer Liquid Biopsy Market (USD Million)
  • Table 12.28 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2022
  • Table 12.29 Non-Invasive Cancer Diagnostics Market: Regional Analysis, 2030
  • Table 12.30 Biocept Revenues, 2012- H1 2015 (USD Million)
  • Table 12.31 Genomic Health Revenues, 2010- H1 2015 (USD Million)
  • Table 12.32 Qiagen Revenues, 2010-Q1 2015 (USD Billion)
  • Table 12.33 Qiagen Revenues, Q1 2015, Split by Business Segments (Share in %)
  • Table 12.34 Trovagene Revenues, 2010-Q1 2015 (USD Million)
  • Table 12.35 bioMérieux Revenues, 2011-Q1 2015 (EUR Billion)
  • Table 12.36 bioNexia® FOB versus Guaiac Based Tests: Sensitivity for Positive Results
  • Table 12.37 Cepheid Revenues, 2010- H1 2015 (USD Million)
  • Table 12.38 Cepheid Revenues: Distribution by Type of Sales, 2014 (USD Million)
  • Table 12.39 DiagnoCure Revenues, 2010-H1 2015 (USD Million)
  • Table 12.40 Exact Sciences Revenues, 2010-HI 2015 (USD Million)
  • Table 12.41 Pacific Edge Revenues, 2010-2014 (USD Million)
  • Table 12.42 Lung Cancer Liquid Biopsy Market (USD Million), 2015, 2022, 2030

Listed Companies

The following companies and organisations have been mentioned in this report.

  • 1. A&G Pharmaceutical
  • 2. Accelerate Brain Cancer Cure
  • 3. AcousysBiodevices
  • 4. Addario Lung Cancer Medical Institute
  • 5. Admera Health
  • 6. AdnaGen
  • 7. Affymetrix
  • 8. Agena Bioscience
  • 9. Almac Group
  • 10. America’s Choice Provider Network
  • 11. American Lung Association
  • 12. Angle plc
  • 13. Anixa Diagnostics Corporation
  • 14. ApoCell
  • 15. ARUP Laboratories
  • 16. Astellas Pharma
  • 17. AstraZeneca
  • 18. Astute Medical
  • 19. Aviva Biosciences
  • 20. Barts Cancer Institute
  • 21. Bayer Healthcare
  • 22. BC Cancer Agency
  • 23. BGI Tech Solutions
  • 24. Biocartis
  • 25. Biocept
  • 26. Biodesix
  • 27. BioFluidica
  • 28. bioMerieux
  • 29. Biosense Medical
  • 30. Biotype Diagnostics
  • 31. BioView
  • 32. Boreal Genomics
  • 33. Brigham and Women's Hospital
  • 34. Canopus Bioscience
  • 35. Catholic Health Initiatives Center
  • 36. Clarient
  • 37. ClearbridgeBioMedics
  • 38. Clovis Oncology
  • 39. CollabRx
  • 40. Columbia University
  • 41. Comprehensive Cancer Center
  • 42. COPAN
  • 43. CreatvMicroTech
  • 44. Cubist Pharmaceuticals
  • 45. CynvenioBiosystems
  • 46. CytoTrack
  • 47. CytoLumina Technologies
  • 48. Dana Farber Cancer Institute
  • 49. Datar Generics
  • 50. Denovo Sciences
  • 51. DermTech
  • 52. DiagnoCure
  • 53. Diagnologix
  • 54. Digene Corporation
  • 55. Drug Response Dx
  • 56. EKF Molecular Diagnostics
  • 57. Eli Lilly
  • 58. Epic Sciences
  • 59. Epigenomics
  • 60. European Medical Network for Translational Research in Ovarian Cancer
  • 61. Exact Sciences
  • 62. Exosome Diagnostics
  • 63. Exosomics Siena
  • 64. Fairview Health Services
  • 65. FedMed
  • 66. Flatiron Health
  • 67. Fluxion Biosciences
  • 68. Foundation Medicine
  • 69. Fraunhofer Institute for Cell Therapy and Immunology
  • 70. Genomic Health
  • 71. Genoptix
  • 72. Gensignia
  • 73. GlaxoSmithKline
  • 74. Guangdong Medical College
  • 75. Guardant Health
  • 76. HainLifescience
  • 77. HansaBioMed
  • 78. Healthscope Pathology
  • 79. Hitachi High-Technologies
  • 80. iCellate Medical
  • 81. Illumina
  • 82. Incyte Genomics
  • 83. Inivata
  • 84. Insight Genetics
  • 85. Ipsen
  • 86. Ironwood Pharmaceuticals
  • 87. IVDiagnostics
  • 88. Janssen Diagnostics
  • 89. OHSU Knight Cancer Institute
  • 90. Labcorp
  • 91. London Health Sciences Centre
  • 92. Louisiana State University
  • 93. Massachusetts General Hospital
  • 94. Mayo Clinic
  • 95. Mayo Medical Laboratory Network
  • 96. MD Anderson Cancer Center
  • 97. MDx Health
  • 98. Medical University of Vienna
  • 99. MELA Sciences
  • 100. Merck Serono
  • 101. MiNDERA
  • 102. MolecularMD
  • 103. Molecular Pathology Laboratory Network
  • 104. Natera
  • 105. National Cancer Institute
  • 106. NeoGenomics Laboratory
  • 107. Novartis
  • 108. Novigenix
  • 109. Ortho Biotech Oncology Research & Development
  • 110. Pacific Edge
  • 111. Palex Medical
  • 112. Pathway Genomics
  • 113. PathQC
  • 114. Personal Genome Diagnostics
  • 115. Promega Corporation
  • 116. Prostate Cancer Foundation
  • 117. Qiagen
  • 118. Quanterix
  • 119. Quest Diagnostics
  • 120. RainDance Technologies
  • 121. Rarecells Diagnostics
  • 122. RareCyte
  • 123. Roche
  • 124. Rosetta Genomics
  • 125. Roswell Park Cancer Institute
  • 126. Royal Philips Electronics
  • 127. Rutgers New Jersey Medical School
  • 128. SAIC-Frederick
  • 129. Sarah Cannon Research Institute
  • 130. ScheBo
  • 131. ScreenCell
  • 132. Siemens
  • 133. Sequenom
  • 134. Shimadzu
  • 135. Shuwen Biotech
  • 136. Signal Genetics
  • 137. Signature Diagnostics
  • 138. Silicon Biosystems
  • 139. SIMSYS
  • 140. Skyline Diagnostics
  • 141. Southern California Permanente Medical Group
  • 142. SRI International
  • 143. StableBody Technologies
  • 144. Stiefel Laboratories
  • 145. Strand Life Sciences
  • 146. SysmexInostics
  • 147. Tan TockSeng Hospital
  • 148. Targeted Diagnostics & Therapeutics
  • 149. Technion-Israel Institute of Technology
  • 150. The Valld’Hebron Institute of Oncology
  • 151. Thermo Fisher Scientific
  • 152. Thomas Jefferson University
  • 153. Tokai Pharmaceuticals
  • 154. Transgenomic
  • 155. Trovagene
  • 156. Tumour Bank Ovarian Cancer Network
  • 157. University of California
  • 158. University of Dusseldorf
  • 159. University of Michigan
  • 160. University of Nijmegen
  • 161. University of Southern California
  • 162. University of Texas
  • 163. Uppsala BIO
  • 164. Vancouver Prostate Centre
  • 165. Veolia Environnement
  • 166. Veracyte
  • 167. Veridex
  • 168. Viatar CTC Solutions
  • 169. Virginia Commonwealth University
  • 170. Vitatex
  • 171. VolitionRx

Back to Top